PE20060560A1 - Anticuerpos de interleucina-4 humana - Google Patents

Anticuerpos de interleucina-4 humana

Info

Publication number
PE20060560A1
PE20060560A1 PE2005000884A PE2005000884A PE20060560A1 PE 20060560 A1 PE20060560 A1 PE 20060560A1 PE 2005000884 A PE2005000884 A PE 2005000884A PE 2005000884 A PE2005000884 A PE 2005000884A PE 20060560 A1 PE20060560 A1 PE 20060560A1
Authority
PE
Peru
Prior art keywords
human interleukin
antibody
antibodies
cdr2
cdr3
Prior art date
Application number
PE2005000884A
Other languages
English (en)
Inventor
Herrera Jose M Carballido
Vries Jan E De
Christoph Schwaerzler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417301A external-priority patent/GB0417301D0/en
Priority claimed from GB0417306A external-priority patent/GB0417306D0/en
Priority claimed from GB0417305A external-priority patent/GB0417305D0/en
Priority claimed from GB0417303A external-priority patent/GB0417303D0/en
Priority claimed from GB0417302A external-priority patent/GB0417302D0/en
Priority claimed from GB0417304A external-priority patent/GB0417304D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20060560A1 publication Critical patent/PE20060560A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

REFERIDA A UN ANTICUERPO ESPECIFICO DE IL-4 HUMANA, EL CUAL SE ENLAZA A LA INTERLEUCINA-4 HUMANA CON UNA CONSTANTE DE DISOCIACION Kd IGUAL O MENOR QUE 800 pM. EL ANTICUERPO TIENE UN PRIMER DOMINIO QUE COMPRENDE, EN SECUENCIA, LAS REGIONES HIPERVARIABLES CDR1, CDR2 Y CDR3 Y UN SEGUNDO DOMINIO QUE COMPRENDE, EN SECUENCIA, LAS REGIONES CDR1', CDR2' Y CDR3'. DICHO ANTICUERPO ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR IL-4 Y/O IgE TALES COMO ENFERMEDADES ALERGICAS, ENFERMEDADES AUTOINMUNES, DESORDENES DEL SISTEMA DIGESTIVO, ENTRE OTROS
PE2005000884A 2004-08-03 2005-08-01 Anticuerpos de interleucina-4 humana PE20060560A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0417301A GB0417301D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417306A GB0417306D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417305A GB0417305D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417303A GB0417303D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417302A GB0417302D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417304A GB0417304D0 (en) 2004-08-03 2004-08-03 Organic compounds

Publications (1)

Publication Number Publication Date
PE20060560A1 true PE20060560A1 (es) 2006-06-27

Family

ID=35457817

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000884A PE20060560A1 (es) 2004-08-03 2005-08-01 Anticuerpos de interleucina-4 humana

Country Status (29)

Country Link
US (2) US7740843B2 (es)
EP (2) EP1817343B1 (es)
JP (1) JP4808712B2 (es)
KR (1) KR101245996B1 (es)
CN (1) CN101001877B (es)
AR (1) AR050044A1 (es)
AU (1) AU2005268932B2 (es)
BR (1) BRPI0514124B8 (es)
CA (1) CA2574289C (es)
CY (1) CY1115524T1 (es)
DK (1) DK1817343T3 (es)
EC (1) ECSP077222A (es)
ES (1) ES2504415T3 (es)
HK (1) HK1109158A1 (es)
HR (1) HRP20140888T1 (es)
IL (1) IL180789A (es)
MA (1) MA28981B1 (es)
MX (1) MX2007001342A (es)
MY (1) MY141851A (es)
NO (1) NO20070854L (es)
NZ (1) NZ552637A (es)
PE (1) PE20060560A1 (es)
PL (1) PL1817343T3 (es)
PT (1) PT1817343E (es)
SG (1) SG155177A1 (es)
SI (1) SI1817343T1 (es)
TN (1) TNSN07036A1 (es)
TW (1) TWI356828B (es)
WO (1) WO2006013087A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2384767B1 (en) * 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业（上海）股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
AU2020231343A1 (en) 2019-03-06 2021-10-21 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
AU2020240132A1 (en) 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
CN117327181A (zh) * 2020-06-22 2024-01-02 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
US20230220089A1 (en) 2021-12-30 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
HU211059B (en) 1988-02-02 1995-10-30 Schering Biotech Corp Method for producing pharmaceutical compositions usable for reducing immunglobulin e responses, containing human il-4 antibodies
CA2071908C (en) * 1989-12-20 2002-04-30 Lata Ramanathan Antibody antagonists of human interleukin-4
ATE171472T1 (de) * 1992-02-19 1998-10-15 Schering Corp Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
WO1994004180A2 (en) 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
ATE286510T1 (de) * 1993-09-07 2005-01-15 Smithkline Beecham Corp In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20020002132A1 (en) * 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
EP1590364B1 (en) 2002-12-16 2011-10-05 Genmab A/S Human monoclonal antibodies against interleukin 8 (il-8)
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine

Also Published As

Publication number Publication date
CY1115524T1 (el) 2017-01-04
CA2574289A1 (en) 2006-02-09
WO2006013087A8 (en) 2007-03-01
AR050044A1 (es) 2006-09-20
HRP20140888T1 (hr) 2014-10-24
AU2005268932A1 (en) 2006-02-09
ES2504415T3 (es) 2014-10-08
EP1817343A1 (en) 2007-08-15
KR20070047299A (ko) 2007-05-04
CA2574289C (en) 2014-09-16
CN101001877B (zh) 2012-09-26
ECSP077222A (es) 2007-03-29
KR101245996B1 (ko) 2013-03-20
TNSN07036A1 (en) 2008-06-02
CN101001877A (zh) 2007-07-18
MY141851A (en) 2010-07-16
AU2005268932B2 (en) 2009-06-25
IL180789A (en) 2017-01-31
NZ552637A (en) 2010-02-26
EP2327726A3 (en) 2012-07-11
US20080241160A1 (en) 2008-10-02
JP4808712B2 (ja) 2011-11-02
DK1817343T3 (da) 2014-09-15
EP1817343B1 (en) 2014-06-25
PL1817343T3 (pl) 2014-11-28
EP2327726A2 (en) 2011-06-01
SG155177A1 (en) 2009-09-30
TWI356828B (en) 2012-01-21
BRPI0514124B1 (pt) 2017-01-31
US20100254993A1 (en) 2010-10-07
MA28981B1 (fr) 2007-11-01
WO2006013087A1 (en) 2006-02-09
JP2008507985A (ja) 2008-03-21
BRPI0514124B8 (pt) 2021-05-25
PT1817343E (pt) 2014-09-09
TW200617024A (en) 2006-06-01
IL180789A0 (en) 2007-06-03
MX2007001342A (es) 2007-04-02
SI1817343T1 (sl) 2014-09-30
US7740843B2 (en) 2010-06-22
NO20070854L (no) 2007-04-24
HK1109158A1 (en) 2008-05-30
BRPI0514124A (pt) 2008-05-27

Similar Documents

Publication Publication Date Title
PE20060560A1 (es) Anticuerpos de interleucina-4 humana
PE20050925A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
PE20140247A1 (es) Anticuerpos anti-cd38
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20180499A1 (es) Anticuerpos de union a tau
PH12019500545A1 (en) Cd3 binding antibodies
CO2019007844A2 (es) Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefálica
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
MX2018016404A (es) Anticuerpos de union a cd3.
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
PE20141478A1 (es) Polipeptidos de anticuerpos que antagonizan cd40l
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
ECSP11010911A (es) Anticuerpos contra la il17 humana y usos de los mismos
ECSP088751A (es) Anticuerpos contra la il-22 humana y usos para los mismos
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
PE20081899A1 (es) Anticuerpos anti-ige
MX2021009674A (es) Receptores de celulas t vgamma9vdelta2 humanas que se unen a inmunoglobulinas.
PE20090689A1 (es) Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
PE20200695A1 (es) Anticuerpos que reconocen tau
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
PE20120014A1 (es) Anticuerpos humanos de alta afinidad contra pcsk9
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed